The pharmaceutical industry faces a major challenge which has limited the ability to develop effective new drugs for CNS disorders. A session at the Dementia Discovery Fund’s Annual Forum, led by Hugh Marston of Boehringer Ingelheim and Ruth McKernan of the Dementia Discovery Fund, pointed to a specific gap in current capabilities that is limiting the development of new therapies: a need for frequent measures - made at home - to fully understand the trajectory of disease and to see if a drug works.
Over the course of a year a panel of scientists from global pharma, convened by DDF, worked to define the optimal suite of tools that could measure both progression of disease in patients and outcome in clinical trials.
At the same time, BrainWaveBank Ltd, had been developing a unique suite of tools to objectively measure memory and other core brain functions. The Pharma panel had identified 6 important requirements and BrainWaveBank had 3 of them. Their ‘EEG at home’ technology was core, able to record brain activity, precisely synchronised to a set of bespoke tablet-based functional tests along with a scalable AI-driven analytics platform, the ideal platform for integrating additional brain function tests.
Cumulus Neuroscience was formed in 2020 by combining BrainWaveBank with additional new technologies to create the single platform. It was funded by investment from the Dementia Discovery Fund, LifeArc, the UK Futures Fund alongside Brainwavebank’s existing investors.
Six Pharma companies have also contributed and the pharma partnership continues to actively drive the requirements of the platform and are supporting Cumulus’ first study in Alzheimer’s disease starting later this year.